Journal Article Summary
The article investigates the use of mirtazapine, an antidepressant, as a potential treatment for severe breathlessness in patients with advanced lung diseases. Breathlessness is a common and distressing symptom that significantly impacts the quality of life and can lead to increased disability and healthcare usage. Current treatment options are limited, and there is a need for new therapies that can effectively alleviate this symptom, making this research particularly relevant for patients suffering from conditions like chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD).
In this study, 64 patients were recruited from three medical centers and randomly assigned to receive either mirtazapine or a placebo for 28 days. The trial aimed to assess the feasibility of conducting a larger study, focusing on recruitment rates and participant retention. Most participants had COPD or ILD, and the study found that while there were no significant differences in breathlessness ratings between the mirtazapine and placebo groups, the trial successfully met its recruitment goals and demonstrated good tolerability and safety for mirtazapine.
Despite the promising results, the study has limitations, including a small sample size and the short duration of treatment. Additionally, the findings may not be generalizable to all patients with advanced lung disease, as many were excluded due to existing antidepressant use. Patients considering mirtazapine for breathlessness should discuss this option with their healthcare provider, especially regarding potential interactions with other medications and individual health conditions.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Higginson Irene J, Wilcock Andrew, Johnson Miriam J, Bajwah Sabrina, Lovell Natasha, Yi Deokhee, Hart Simon P, Crosby Vincent, et al.. Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). Thorax 2020. DOI: 10.1136/thoraxjnl-2019-213879. PMID: 31915308. PMCID: PMC7029228.
Featured Pill Pals Product
Mirtazapine 15 mg Tablets --- 30 Count --- Generic for Remeron --- Rising Pharma
Mirtazapine 15 mg Tablets — 30 Count — Generic for Remeron — Rising Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
